Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)

Phase 2/3 Completed 288 enrolled Alexion Pharmaceuticals, Inc. CTI Clinical Trial and Consulting Services · collab

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study was to determine if eculizumab is safe and could be used to prevent delayed graft function (DGF) following kidney transplantation.

Timeline

Start: 2014-08-21
Primary completion: 2016-11-22
Completion: 2016-11-22

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Eculizumab	Monoclonal antibody	—	Intravenous

Indications

No indication recorded.